n/a
Article Publish Status: FREE
Abstract Title:

Glycopeptide prevents the development and progression of acute colitis by regulating the composition and diversity of the gut microbiota in mice.

Abstract Source:

Front Cell Infect Microbiol. 2022 ;12:921075. Epub 2022 Aug 9. PMID: 36017369

Abstract Author(s):

Yichun Huang, Yinghui Zheng, Fengmei Yang, Yicheng Feng, Kunyao Xu, Jun Wu, Shuang Qu, Zhexiong Yu, Fu Fan, Lu Huang, Meng Qin, Zhanlong He, Kaili Nie, Kwok-Fai So

Article Affiliation:

Yichun Huang

Abstract:

In most cases, recurrent chronic colitis is caused by the recurrence of acute colitis after incomplete recovery and re-exposure to irritating factors, and the gut microbiome, which is the largest micro-ecosystem in the human body, plays a crucial role in the development of colitis. Plant polysaccharides have always been reported to have the ability for anti-inflammation, and they are closely related to the gut microbiome.Glycopeptide (LbGP), the most potent component obtained by further isolation and purification fromfruit, has been shown to inhibit inflammation in animal models. However, its therapeutic efficacy in colitis and its mechanism in gut microbiota regulation have not been fully studied. In our study, the dextran sulfate sodium (DSS)-induced mouse model was used to dynamically evaluate the effect of LbGP in the treatment of acute colitis and the mechanism from the perspective of the gut microbiome through the 16S rDNA sequence. The results showed that LbGP treatment significantly alleviated acute colitis and improved the gut microbiome compared with that in the model group. Harmful bacteria, such asspp. and, were inhibited and probiotics, such asspp.,spp., andspp., were increased by LbGP treatment. Further, a Random Forest analysis with 10-fold cross-validation identified a family namedrepresenting colitis development and recovery upon LbGP treatment. In conclusion, our study demonstrated the capability of LbGP to prevent the development of acute colitis by regulating the composition and diversity of the gut microbiota and highlighted the dynamic process of gut microbiota with the colitis progression. Further, it provides evidence to develop LbGP as a functional food supplement and future drug acting on intestinal disease.

Study Type : Animal Study
Additional Links

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.